Brazil's 2nd-largest telehealth CEO on how Hims & Hers should enter Brazil 🇧🇷

<p>Thanks to our partner: Superpower - https://superpower.com</p><p><br /></p><p>In episode 82, Jonathan Stern talks with Abrahão Fecury, co-founder and CEO of Eles &amp; Elas, a Brazilian telehealth company built on the Hims playbook and now at about R$4.5 million (~$1 million USD) in annual revenue, growing about +10% a month. Weight loss is about 70% of that (compounded tirzepatide) at a 54% gross margin, with hair loss and mental health smaller and more profitable. Fecury walks through cash-pay pharmacies, Meta and WhatsApp customer acquisition, and how ANVISA's summer ban on Voy changed the category. We close with a discussion about Hims &amp; Hers - where he says, if Hims wants to expand into Brazil, it should "absolutely buy" a telehealth in Brazil (like Voy or Eles &amp; Elas) vs building everything itself. </p><p><br /></p><p>00:00 - Sponsor: Superpower</p><p>04:51 - Revenue of R$4.5 million (~$1 million USD)</p><p>10:25 - Margins of each category</p><p>13:35 - Brazil healthcare 101</p><p>16:43 - 1 in 4 adults in Brazil has obesity</p><p>19:22 - Meta Ads brings in 80% of customers</p><p>24:30 - Why ANVISA banned Voy, then reversed it on August 5</p><p>28:32 - Voy "more than 10x Eles &amp; Elas' revenue"</p><p>30:57 - Generic semaglutide margin is only 5-10%</p><p>34:26 - Lilly suing in Brazil too</p><p>35:30 - Paraguay shenanigans</p><p>40:38 - Hims should buy a telehealth to expand into Brazil</p><p>48:34 - Other countries in LatAm</p><p><br /></p><p>Disclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions.</p>